The annual wholesale cost of Aduhelm, the Alzheimer's drug from pharmaceutical company Biogen, is already 50% off, yet its value is several thousand dollars.
The drug caused controversy because its approval in the United States led to the resignation of members of a panel who refused to give their approval.